DBVT Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of -- compared to DBV Technologies SA's net margin of -93.73%. DBV Technologies SA's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

DBV Technologies SA has a consensus price target of $14.88, signalling upside risk potential of 57.13%. On the other hand Ascendis Pharma AS has an analysts' consensus of $229.05 which suggests that it could grow by 32.48%. Given that DBV Technologies SA has higher upside potential than Ascendis Pharma AS, analysts believe DBV Technologies SA is more attractive than Ascendis Pharma AS.

DBV Technologies SA has a beta of -0.624, which suggesting that the stock is 162.448% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.446%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. DBV Technologies SA's net income of -$27.1M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 25.75x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to DBV Technologies SA's net margin of -170.14%. DBV Technologies SA's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

DBV Technologies SA has a consensus price target of $14.88, signalling upside risk potential of 57.13%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 319.71%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.624, which suggesting that the stock is 162.448% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.924, suggesting its more volatile than the S&P 500 by 192.353%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. DBV Technologies SA's net income of -$27.1M is lower than Cellectis SA's net income of -$18.1M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 2.81x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to DBV Technologies SA's net margin of -52.18%. DBV Technologies SA's return on equity of -- beat Edap TMS SA's return on equity of -49.1%.

DBV Technologies SA has a consensus price target of $14.88, signalling upside risk potential of 57.13%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 236.26%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.624, which suggesting that the stock is 162.448% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.015, suggesting its less volatile than the S&P 500 by 98.469%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.3M. DBV Technologies SA's net income of -$27.1M is lower than Edap TMS SA's net income of -$7.4M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 0.95x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Genfit SA's return on equity of --.

DBV Technologies SA has a consensus price target of $14.88, signalling upside risk potential of 57.13%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 113.43%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.624, which suggesting that the stock is 162.448% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.148, suggesting its more volatile than the S&P 500 by 14.837%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. DBV Technologies SA's net income of -$27.1M is higher than Genfit SA's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 2.83x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.